Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 6Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × brexucabtagene autoleucel × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡